With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Global Health Innovation and Access: Sustainable Business Models
CGD—in collaboration with the broader global health community, health economists, industry partners, and policymakers—is helping develop and drive an evidence-based policy agenda to make health product markets work for the poor. For millions of people around the world, life-saving drugs remains out of reach because economic incentives to drive their development and commercialization are lacking. CGD research and analysis systematically works to address market failures that span the entire value chain, from early stage pharmaceutical research to market competition, quality assurance, and supply chain efficiency.
Upstream, CGD research aims to kickstart R&D for these neglected diseases while simultaneously ensure affordable access once products are approved for use. Building on CGD’s Advance Market Commitment model, CGD’s Market-Driven Value-Based Advancement Commitment (MVAC) model—developed in partnership with the Office of Health Economics for the specific case of TB drugs—measures future demand in middle-income countries through health technology assessment (HTA), uses country advance purchase commitments—set at locally affordable prices—to resolve future market uncertainty, and crowds in private-sector capital to drive the priority research.
Our vision is one where the best science and the best organizations—public and private—partner to meet priority health needs for all. In the race to develop a vaccine for COVID-19, CGD experts are currently focused on leveraging the "missing middle"—the private sector and middle-income countries, as well as developed economies. Read about their proposal for a benefits-based advanced market commitment (BBAMC).
In addition to the work linked above and the CGD publications, blogs, and events in the cards below, please find additional related materials here:
Decisions about which type of patients receive what interventions, when, and at what cost often result from ad hoc, nontransparent processes driven more by inertia and interest groups than by science, ethics, and the public interest. Reallocating a portion of public and donor monies toward the most cost-effective health interventions would save more lives and promote health equity.